Mobilizing the Immune System to Target Gastrointestinal Cancers

Oncolytics Biotech Inc. (Nasdaq: ONCY) is a clinical-stage biopharmaceutical company developing pelareorep, a first-in-class intravenous immunotherapeutic agent, as a platform treatment for gastrointestinal cancers including pancreatic, colorectal, and anal cancer.

5 Reasons Investors Are Watching Oncolytics Biotech Inc.

First-in-Class Immunotherapy Platform –Pelareorep is an investigational, first-in-class intravenous dsRNA immunotherapeutic agent with a safety profile demonstrated across more than 1,300 patients to date, and it holds FDA Fast Track Designation for advanced pancreatic cancer and second-line and later anal cancer.

Validated Pharmaceutical Partnerships – Roche supplies its checkpoint inhibitor atezolizumab for use in Oncolytics-sponsored studies, and the company also collaborates with Pfizer, Merck Serono, Incyte, and Adlai Nortye to evaluate pelareorep in combination with their therapies.

Strong Early Data Across Three GI Cancers – In metastatic pancreatic cancer, pelareorep combined with chemotherapy and atezolizumab produced a 45% one-year survival rate and a 62% objective response rate in the GOBLET Cohort 1 study. In KRAS-mutant, microsatellite-stable metastatic colorectal cancer, the REO 022 trial reported a median overall survival of 27 months versus 11.2 months for standard treatment. In anal cancer, pelareorep combined with atezolizumab produced objective response rates of roughly 29 to 30 percent, compared with 13.8% for the only FDA-approved immunotherapy in that setting.

Extended Patent Protection to 2044– A new U.S. patent secured in June 2026 extends commercial manufacturing protection for pelareorep to 2044, part of a portfolio of 137 patents including 11 U.S. and 7 Canadian patents. The company also filed a $250 million mixed securities shelf registration in April 2026 to help fund ongoing clinical development.

New Leadership and Corporate Redomestication– Oncolytics completed a corporate domestication from Alberta, Canada to Nevada, USA in April 2026 and relocated its headquarters to San Diego, California, while retaining an office in Calgary. New leadership includes CEO Jared Kelly, and the company recently strengthened its team with the June 2026 promotion of John McAdory to Chief Operating Officer and the addition of board member Steve Glover, who previously chaired Ambrx Biopharma through its roughly $2 billion acquisition by Johnson & Johnson.

Learn More

Identifying The Opportunity

KEY LEVELS

_{Key Level: $0.8780 (9.24%)}

_{Key Level: $0.9506 (18.42%)}

_{Key Level: $1.01 (26.19%)}

_{Support Level: 0.7522}

About Oncolytics Biotech Inc.

Oncolytics Biotech Inc. (Nasdaq: ONCY) is a clinical-stage biopharmaceutical company focused on developing pelareorep, a first-in-class double-stranded RNA immunotherapeutic agent, as a platform treatment for gastrointestinal cancers. Headquartered in San Diego, California, with a continuing office in Calgary, Alberta, the company has built a focused pipeline spanning pancreatic, colorectal, and anal cancer. Its intravenous immunotherapy platform is designed to prime the immune system to recognize and attack tumors when combined with chemotherapy and checkpoint inhibitors. Through strategic partnerships with Roche, Pfizer, Merck Serono, Incyte, and Adlai Nortye, a growing intellectual property portfolio, and a newly reconstituted leadership team, Oncolytics is working to position itself at the forefront of the rapidly advancing field of immuno-oncology for gastrointestinal cancers.

Oncolytics Biotech Inc.

Platform Immunotherapy for Gastrointestinal Cancers

Oncolytics' platform is built around pelareorep, an intravenous dsRNA immunotherapeutic designed to prime the immune system against tumors, working alongside chemotherapy and checkpoint inhibitors rather than as a standalone agent.

Pelareorep's design allows it to be combined with a range of chemotherapy regimens and checkpoint inhibitors, enabling efficient evaluation across multiple gastrointestinal cancer types through partner-sponsored studies.

Pelareorep has demonstrated a favorable safety profile across more than 1,300 patients to date, providing early human validation for the platform across multiple gastrointestinal cancer types.

The same platform is being evaluated across three gastrointestinal cancer indications:
mPDAC → gemcitabine, nab-paclitaxel, and atezolizumab
mCRC (KRAS-mutant, MSS) → FOLFIRI and bevacizumab

Anal cancer (SCAC) → combined with atezolizumab, with objective response rates of up to 30 percent across the three largest gastrointestinal cancer indications.

Operational Momentum and Scaling

Oncolytics is building a focused gastrointestinal oncology pipeline around a single lead asset, pelareorep, using partner-sponsored and academic collaborations to extend its reach without funding every trial alone.
Pharmaceutical collaborations with Roche, Pfizer, Merck Serono, Incyte, and Adlai Nortye help validate pelareorep and expand its evaluation across combination regimens.
A planned registration-focused study in KRAS-mutant, microsatellite-stable colorectal cancer aims to build on early REO 022 data and expand pelareorep's path toward regulatory review.

Positioning for Long-Term Growth

Oncolytics is building a focused gastrointestinal oncology business centered on pelareorep, using partnerships to extend its reach while reducing reliance on dilutive financing alone.
Collaborations with Roche, Pfizer, Merck Serono, Incyte, and Adlai Nortye validate pelareorep's platform potential and expand its evaluation across combination regimens.
A new U.S. patent secured in June 2026 strengthens pelareorep's commercial manufacturing protection through 2044, supporting the company's long-term intellectual property position.

Introducing the Leadership Team of Oncolytics Biotech Inc. (Nasdaq: ONCY)

Jared Kelly

Chief Executive Officer & Director

Jared Kelly serves as Chief Executive Officer and Director of Oncolytics Biotech Inc., leading the company's strategic focus on pelareorep, its investigational platform immunotherapy for gastrointestinal cancers. Under his leadership, Oncolytics has advanced pelareorep through partner sponsored and academic collaborations, secured Fast Track Designation from the FDA for two indications, completed the company's corporate domestication from Alberta, Canada to Nevada, USA, and relocated its headquarters to San Diego, California. He oversees the company's clinical development partnerships with organizations including Roche, Pfizer, Merck Serono, Incyte, and Adlai Nortye, as well as its capital markets strategy as a clinical stage biopharmaceutical company.

Kirk Look, CA, MSJ

Chief Financial Officer

Kirk Look serves as Chief Financial Officer of Oncolytics Biotech Inc. He oversees the company's financial operations as a clinical stage biopharmaceutical company funding its trials through equity and other securities offerings, including the company's $250 million mixed securities shelf registration filed with the SEC in April 2026. He works closely with the company's auditor, Ernst & Young LLP, and supports the finance and reporting functions tied to the company's SEC filings, including its 10-Q and 10-K disclosures.

During his tenure, Oncolytics has strengthened its balance sheet through capital markets activity, advanced pelareorep across three gastrointestinal cancer indications in partnership with Roche, Pfizer, Merck Serono, Incyte, and Adlai Nortye, and supported the company's transition to its new Nevada domicile and San Diego headquarters.

Thomas C. Heineman, MD, PhD

Chief Medical Officer

Thomas C. Heineman, MD, PhD serves as Chief Medical Officer of Oncolytics Biotech Inc. He leads the clinical development strategy for pelareorep, the company's investigational dsRNA immunotherapeutic, across its three target gastrointestinal cancer indications: metastatic pancreatic ductal adenocarcinoma, KRAS mutant microsatellite stable metastatic colorectal cancer, and unresectable squamous cell anal carcinoma. He works closely with the company's academic and institutional collaborators, including Mayo Clinic, Duke University, and the Rutgers Cancer Institute of New Jersey, and supports the company's regulatory interactions with the FDA, including its Fast Track Designations and its pursuit of a Type C meeting to discuss an accelerated approval pathway.

We get our information from SEC filings and verified public sources.

Stay Ahead. Stay Informed. Stay Profitable.

Subscribe to See What They're Watching

Get Priority Access

Sources

https://www.oncolyticsbiotech.com/ https://www.sec.gov/ (ONCY SEC Filings) https://www.stocktitan.net/ (SEC filings tracker and news feed) https://finance.yahoo.com/ https://www.google.com/finance/ https://stockanalysis.com/ https://www.tradingview.com/symbols/NASDAQ-ONCY/

Disclaimer

Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/.

By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.

This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.

Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.

The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.

We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.

Pursuant to an agreement between Oncolytics Biotech and Virtus Media Group LLC, Virtus Media has been hired to publicly disseminate information about ticker $ONCY via digital communications beginning August 10th 2026 ending September 7th, 2026. Virtus will be paid $80,000 from Oncolytics Biotech LLC.